SCHEMBL5828022

SCHEMBL5828022

CC(=O)OC[C@H]1O[C@H](n2cc(C3=C(c4c[nH]c5ccccc45)C(=O)N(COCc4ccccc4)C3=O)c3cccnc32)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
THRB P10828 1/20 0.39
HIF1A Q16665 1/20 0.39
PRKCA P17252 1/20 0.38
AKT1 P31749 1/20 0.38
PTK2 Q05397 1/20 0.38
SIRT2 Q8IXJ6 1/20 0.37
ALDH1A1 P00352 5/20 0.37
MAPT P10636 3/20 0.37
TP53 P04637 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
PARP1 P09874 1/20 0.36
PRKAB2 O43741 1/20 0.36
PRKAG1 P54619 1/20 0.36
PRKAA2 P54646 1/20 0.36
PRKAA1 Q13131 1/20 0.36
PRKAG3 Q9UGI9 1/20 0.36
PRKAG2 Q9UGJ0 1/20 0.36
PRKAB1 Q9Y478 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5828025 1.00 LMNA (0.39) LMNASMN1; SMN2THRBHIF1APRKCA
SCHEMBL5828106 0.94 LMNA (0.41) LMNASMN1; SMN2THRBHIF1APRKCA
SCHEMBL5828932 0.89 LMNA (0.45) LMNASMN1; SMN2THRBHIF1APRKCA
SCHEMBL5827873 0.87 LMNA (0.39) LMNASMN1; SMN2THRBHIF1APRKCA
SCHEMBL5828685 0.86 PTGS2 (0.43) LMNASMN1; SMN2THRBHIF1APRKCA
SCHEMBL5828553 0.85 PTGS2 (0.47) LMNASMN1; SMN2THRBHIF1APRKCA
SCHEMBL5828083 0.82 PTGS2 (0.44) LMNASMN1; SMN2THRBHIF1APRKCA
SCHEMBL5827541 0.81 LMNA (0.47) LMNASMN1; SMN2THRBHIF1APRKCA
SCHEMBL5827622 0.78 LMNA (0.42) LMNASMN1; SMN2THRBHIF1APRKCA
SCHEMBL6197547 0.76 LMNA (0.47) LMNASMN1; SMN2THRBHIF1APRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7001906-B2 Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives LES LABORATOIRES SERVIER (FR) 2006-02-21 US disclosed
US-20040152721-A1 Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives LES LABORATOIRES SERVIER (FR) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152721-A1 Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives PYM1, PNPO, IDO1 LMNA 4488/4885SMN1; SMN2 4557/4885THRB 2620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.